Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower RespiratoryTract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United Sta
- Katherine Fleming-Dutra; Jefferson Jones; Lauren Roper; Mila Prill; Ismael Ortega-Sanchez; Danielle Moulia
Access Resources
About
This article discusses the use of Pfizer's RSV vaccine for pregnant women to protect infants from RSV-related lung disease. The CDC recommends giving the vaccine between 32-36 weeks of pregnancy, mainly from September to January in the U.S. It highlights that either this maternal vaccination or an infant antibody treatment called nirsevimab can prevent severe RSV in babies, but both are not needed for most infants. The report also mentions potential risks like preterm birth and provides guidance on using these preventive measures effectively.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.